CHIESI FARMACEUTICI S.P.A.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1935-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.chiesigroup.com
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1130
- Registration Number
- NCT02986321
Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseAsthma
- Interventions
- Drug: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 28
- Registration Number
- NCT02975843
Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 28
- Registration Number
- NCT02970630
- Locations
- 🇮🇹
Azienda Ospedaliera di Padova, Padova, Italy
🇮🇹Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹Policlinico "A. Gemelli", Rome, Italy
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD
Phase 1
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: CHF6297 (Part 1 - SAD)Drug: Placebo (Part 1 - SAD)Drug: CHF6297 (Part 2 - MAD)Drug: Placebo (Part 2 - MAD)Drug: Placebo (Part 3)Drug: CHF6297 (Part 3)Drug: CHF6297 (Part 4)Drug: Placebo (Part 4)
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2020-04-17
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 118
- Registration Number
- NCT02815488
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF 1535 35/4µg NEXThaler®
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 26
- Registration Number
- NCT02787967
- Locations
- 🇩🇰
BørneAstmaKlinikken, Hans Knudsens Plads 1A,, Copenaghen, Denmark
A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration
Phase 3
Terminated
- Conditions
- Respiratory Distress Syndrome (RDS)
- Interventions
- Combination Product: LISA combination product (Curosurf+catheter CHF6440)
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 33
- Registration Number
- NCT02772081
- Locations
- 🇺🇸
Chiesi Clinical Trial Site 84002, Los Angeles, California, United States
🇺🇸Chiesi Clinical Trial Site 84012, Camden, New Jersey, United States
🇺🇸Chiesi Clinical Trial Site 84024, Manhasset, New York, United States
Cangrelor Neonatal PK/PD and Safety Study
Phase 1
Completed
- Conditions
- Partial Obstruction of Systemic to Pulmonary Artery ShuntComplete Obstruction of Systemic to Pulmonary Artery Shunt
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 22
- Registration Number
- NCT02765633
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers
Phase 1
Completed
- Conditions
- COPD
- Interventions
- Drug: CHF 5993 100/6/12,5 pMDI with Valved Holding ChamberDrug: CHF 5993 100/6/12,5 DPI Test 2Drug: CHF 5993 100/6/12,5 pMDIDrug: CHF 5993 100/6/12,5 pMDI replicateDrug: CHF 5993 100/6/12,5 DPI Test 1
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 50
- Registration Number
- NCT02743013
- Locations
- 🇧🇪
SGS CPU Antwerpen, Antwerpen, Belgium
Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: CHF5259 or Placebo administration
- First Posted Date
- 2016-02-11
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 262
- Registration Number
- NCT02680197
- Locations
- 🇭🇺
Clinical Trial Site 348-005, Komarom, Hungary
🇭🇺Clinical Trial Site 348-002, Létavértes, Hungary
🇭🇺Clinical Trail Site 348-009, Seregélyes, Hungary
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: CHF 5993 100/6/12.5 µgDrug: CHF 1535 100/6 µg
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1153
- Registration Number
- NCT02676076
- Locations
- 🇩🇪
Chiesi Clinical Trial Site 276814, Rostock, Germany
© Copyright 2025. All Rights Reserved by MedPath